Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of NY-303 in advanced hepatocellular carcinoma
MOH_2024-12-19_013793Phase 2Not yet recruiting
- Sponsor
- NAYA Oncology
- Start
- Jul 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CYT-303 in hepatocellular carcinoma (HCC) (3 arms), sponsored by NAYA Oncology. Primary endpoints: Safety and tolerability and Dose selection. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
CYT-303
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on MOH_2024-12-19_013793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-12-19_013793.